1. Home
  2. EARN vs PBYI Comparison

EARN vs PBYI Comparison

Compare EARN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.27

Market Cap

200.3M

Sector

Real Estate

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$6.00

Market Cap

263.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
PBYI
Founded
2012
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.3M
263.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
EARN
PBYI
Price
$5.27
$6.00
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$5.88
$7.00
AVG Volume (30 Days)
314.8K
392.6K
Earning Date
02-20-2026
11-06-2025
Dividend Yield
18.08%
N/A
EPS Growth
N/A
59.87
EPS
N/A
0.74
Revenue
$35,893,000.00
$211,995,000.00
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.27
N/A
P/E Ratio
N/A
$8.08
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$2.58
52 Week High
$6.86
$6.27

Technical Indicators

Market Signals
Indicator
EARN
PBYI
Relative Strength Index (RSI) 50.06 62.57
Support Level $5.15 $5.81
Resistance Level $5.37 $6.27
Average True Range (ATR) 0.09 0.22
MACD 0.01 0.02
Stochastic Oscillator 55.00 63.29

Price Performance

Historical Comparison
EARN
PBYI

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: